July 28, 2026 Agenus Inc. Set to Release Q2 2026 Financial Results and Development Update Agenus Inc. will release its Q2 2026 financial results on August 6, 2026, followed by a webcast discussing its BOT+BAL immunotherapy advancements. The company aims to enhance cancer treatment outcomes through innovative therapies.
July 17, 2026 Agenus Inc. Announces Significant Presentations at ESMO 2026 Agenus Inc. announces three key presentations at ESMO 2026 focused on the BOT+BAL combination therapy for various cancer types. Notable insights from the NEOASIS study on colorectal cancer and real-world data on advanced sarcoma and refractory metastatic colorectal cancer are expected to impact future treatment strategies.
July 13, 2026 Agenus Inc. Secures $340 Million in Oversubscribed Private Placement to Propel Oncology Research Agenus Inc. has raised $340 million through a private placement to support its ROBBIN trial targeting MSS colon cancer with the BOT+BAL regimen. The funding will accelerate clinical research and development, focusing on the promising results from previous studies.
July 06, 2026 Agenus Inc. Reports Promising Long-Term Survival Data for BOT+BAL in Metastatic Colorectal Cancer Agenus Inc. revealed significant three-year data from its Phase 1b trial on BOT+BAL for patients with MSS mCRC, showing a median survival of 21.2 months and a 33% three-year survival rate. These results suggest a transformative potential for treating previously refractory cases.
June 25, 2026 Agenus Inc. Unveils Promising Three-Year Survival Data in Colorectal Cancer Study Agenus Inc. will unveil promising three-year survival data for its colorectal cancer treatment, highlighting the efficacy of botensilimab and balstilimab at ESMO GI 2026. This significant milestone reflects extended follow-up data on patient outcomes and the ongoing commitment to advancing immunotherapy.
June 02, 2026 Agenus Inc. Announces Virtual Annual Shareholders Meeting for 2026 Agenus Inc. will hold its 2026 Annual Shareholders Meeting virtually on June 16, allowing shareholders to join from home. Key details include registration times, voting information, and webcast access, emphasizing the company's commitment to advancing cancer immunotherapy.
May 21, 2026 Agenus Inc. Unveils Promising AI-Driven Insights for Immunotherapy in Metastatic Colorectal Cancer Agenus Inc. announces AI-driven insights linking tumor pathology images to patient responses in immunotherapy for metastatic colorectal cancer. The TARIO-2 model shows promise in predicting clinical outcomes, paving the way for enhanced patient stratification and treatment efficacy.
May 21, 2026 Agenus Reveals Encouraging Phase 2 Melanoma Data at ASCO 2026 Agenus Inc. reported encouraging Phase 2 data on the BOT+BAL combination therapy for advanced melanoma, showing a median overall survival of 16.6 months. The study indicates this treatment may offer hope for patients who have not responded to previous therapies, with a notable 42% two-year survival rate.
May 04, 2026 Agenus Inc. Sets Stage for Financial Insights with Upcoming Q1 2026 Report Agenus Inc. will announce its Q1 2026 financial results on May 11, focusing on its lead therapies botensilimab and balstilimab. The upcoming webcast will outline strategic priorities and clinical progress, crucial for stakeholders in the immuno-oncology sector.
April 21, 2026 Agenus Inc. Set to Showcase Pioneering Phase 2 Data on Botensilimab at ASCO 2026 Agenus Inc. will present four abstracts at ASCO 2026, including the first Phase 2 data for botensilimab, targeting advanced melanoma and colorectal cancer. This showcases their commitment to advancing immunotherapy options for patients with refractory conditions.
April 21, 2026 Agenus Partners with BAP Pharma for Global Access to Innovative Cancer Treatments Agenus Inc. has partnered with BAP Pharma to improve patient access to its cancer therapies, botensilimab and balstilimab, through global access programs. This collaboration aims to streamline operations and facilitate treatment for patients with serious cancers across multiple countries.
April 17, 2026 Agenus Inc. Reports Promising Phase II Data for Innovative Cancer Treatment Agenus Inc. has reported promising results from a Phase II trial targeting PD-1 refractory gastroesophageal cancer, showcasing a 77% disease control rate and significant improvements in survival. The trial explored the combination of investigational therapies and chemotherapy, paving the way for future research in immuno-oncology.
April 03, 2026 Agenus Inc. to Present Phase II Study Results at AACR 2026 Agenus Inc. is set to present data from its Phase II study at the AACR Annual Meeting 2026, focusing on therapies for PD-1 refractory gastroesophageal cancer. Led by Dr. Samuel L. Cytyrn, the study evaluates the efficacy of botensilimab and balstilimab combined with agenT-797. This research addresses critical unmet medical needs in cancer treatment.
April 01, 2026 Agenus Enrolls First Patient in Pivotal BATTMAN Trial for Colorectal Cancer Immunotherapy Agenus has enrolled its first patient in the pivotal BATTMAN trial, aiming to evaluate the efficacy of the BOT+BAL immunotherapy combination in metastatic colorectal cancer. This global study seeks to provide new treatment options for patients with limited alternatives, marking a significant milestone in immuno-oncology.
March 26, 2026 Agenus Inc. to Host Stakeholder Webcast Focused on Advancements in Immunotherapy Agenus Inc. will host a stakeholder webcast focusing on its immunotherapy advancements with botensilimab and balstilimab. Key presentations will cover strategic direction, clinical progress, and patient access initiatives.
March 17, 2026 Agenus Inc. Announces Promising Presentation on Combination Therapy for Colorectal Cancer Agenus Inc. is set to present promising findings on a combination therapy for colorectal cancer at the AACR Annual Meeting 2026. The study explores the use of botensilimab and balstilimab in treating microsatellite stable colorectal cancer, targeting a patient population with limited treatment options. This research could significantly impact future cancer therapies.
March 16, 2026 Agenus Inc. Reports Positive 2025 Results and Expands BOT+BAL Programs Agenus Inc. announced positive financial results for 2025, driven by its BOT+BAL immunotherapy program. The company has initiated a Phase 3 trial and expanded access for patients with refractory cancers, reflecting its commitment to innovative cancer solutions.
March 16, 2026 Agenus Inc. Reports 2025 Annual Results: A Year of Strategic Focus and Financial Resilience Agenus Inc.'s 2025 annual report highlights significant strategic realignment, clinical advancements in immunotherapy, and improved financial outcomes despite ongoing challenges. Key focuses include progress in lead programs, partnerships, and a commitment to innovation amidst legal issues.
March 04, 2026 Agenus Inc. Prepares for Key Financial Update and Strategic Briefing Agenus Inc. is set to announce its fourth quarter and year-end 2025 financial results on March 16, 2026. The company will also host a stakeholder briefing to discuss its strategic plans and the development of key therapies, botensilimab and balstilimab, aimed at improving cancer treatment outcomes.
February 19, 2026 Agenus Unveils Promising Biomarker Data for Immuno-Oncology Treatments Agenus Inc. presented groundbreaking findings on its BOT+BAL therapy for microsatellite-stable metastatic colorectal cancer at the AACR-IO Conference. The Phase 1b trial revealed innovative biomarker insights that challenge traditional patient stratification methods, highlighting the potential for improved outcomes in historically resistant tumor types.
February 09, 2026 Agenus Inc. Set to Showcase Innovative Research at AACR-IO Conference Agenus Inc. will present groundbreaking data on its botensilimab program at the AACR-IO Conference, focusing on treatment for immunologically cold tumors. The research explores the immune response to these tumors and aims to improve therapeutic outcomes for resistant cancer types.
January 21, 2026 Agenus Expands Medical Affairs Infrastructure to Enhance Access to Botensilimab and Balstilimab Agenus Inc. is enhancing its Medical Affairs infrastructure to improve access to its investigational immunotherapy BOT+BAL due to rising demand from oncologists. The company is utilizing regulatory pathways to facilitate treatment access while preparing for a Phase 3 trial to evaluate the therapy's efficacy.
January 20, 2026 Agenus Inc. Set to Host First Stakeholder Webcast of 2026 Agenus Inc. will host its first Stakeholder Webcast on January 28, 2026, focusing on BOT+BAL program advancements and strategic partnerships. Key speakers will discuss global access pathways and the importance of new collaborations in enhancing patient access to innovative cancer therapies.
January 15, 2026 Agenus Inc. Announces $141 Million Collaboration with Zydus Lifesciences Agenus Inc. has announced a $141 million collaboration with Zydus Lifesciences to accelerate the development of its immunotherapy program. The deal includes substantial upfront payments and exclusive rights for Zydus to commercialize key therapies in India and Sri Lanka. This partnership positions Agenus to enhance its manufacturing capacity and advance clinical trials for promising cancer treatments.
January 12, 2026 France Expands Access to Agenus' Botensilimab and Balstilimab for Cancer Treatments Agenus' investigational immunotherapy combination, BOT+BAL, has gained expanded access approval in France, allowing more patients with advanced cancers to receive treatment. This initiative, under the AAC framework, addresses urgent medical needs and enhances early access to innovative therapies.
December 23, 2025 Agenus Inc. Reports Promising Results for Botensilimab and Balstilimab in Ovarian Cancer Agenus Inc. has published positive results from its Phase 1b trial of botensilimab and balstilimab for ovarian cancer, showing a 23% response rate in heavily pretreated patients. This innovative combination offers new hope for those facing platinum-resistant tumors, highlighting a significant advancement in treatment options.
November 19, 2025 Agenus Inc. to Highlight Progress in GI Oncology During Year-End Stakeholder Webcast Agenus Inc. will host a webcast on December 3, 2025, focusing on innovations in GI oncology and colorectal cancer treatment. Key discussions will include insights from expert speakers on immuno-oncology advancements and patient experiences.
November 18, 2025 Agenus Inc. Appoints Dr. José Iglesias as Chief Medical Affairs Officer Agenus Inc. has appointed Dr. José Iglesias as Chief Medical Affairs Officer, effective November 10, 2025. With over 30 years of experience, he will lead the medical strategy for innovative cancer therapies, particularly targeting MSS colorectal cancer through early-access programs.
November 10, 2025 Agenus Inc. Reports Promising Q3 2025 Results Amidst Clinical and Regulatory Advances Agenus Inc. has reported promising Q3 2025 results, highlighting key clinical and regulatory advances, particularly with BOT/BAL for metastatic colorectal cancer in France. The company is launching the BATTMAN trial, aiming to enhance treatment access for patients with refractory cancers while showing impressive financial recovery.
November 10, 2025 Agenus Inc. Reports Q3 2025 Financial Results: A Turning Point in Immuno-Oncology Development Agenus Inc. has reported a net income turnaround in Q3 2025, alongside advancements in its immunotherapy pipeline and strategic collaborations. Despite financial hurdles, the company is positioning for growth as it navigates the biotech landscape.
November 05, 2025 Agenus Inc. Prepares for Q3 2025 Financial Results and Corporate Update Agenus Inc. is set to release its Q3 2025 financial results on November 10, 2025, providing crucial insights into its operations. A stakeholder briefing will follow later in the month to discuss corporate and clinical updates.
October 17, 2025 Agenus Reports Promising Survival Rates for BOT/BAL Combination Therapy Agenus Inc. presented groundbreaking survival data for its BOT/BAL combination therapy at ESMO 2025, showing nearly 39% of patients with refractory tumors alive after two years. The results support further trials and highlight the therapy's potential to transform cancer treatment.
October 16, 2025 Agenus Inc. to Host Stakeholder Briefing Showcasing BOT/BAL Progress Agenus Inc. will host a virtual Stakeholder Briefing on October 21, 2025, to discuss advancements in its BOT/BAL immunotherapy. The session will feature insights from key experts and address the latest findings from the ESMO Congress, culminating in a live Q&A.
August 11, 2025 Agenus Inc. Reports Q2 2025 Financial Results: A Mixed Bag of Growth and Challenges Agenus Inc. reports a net income loss of $28 million for Q2 2025, an improvement from the previous year. Revenue rose to $25.69 million, driven by strategic partnerships and clinical advancements, despite concerns over cash flow and sustainability.
May 15, 2025 Agenus Inc Unveils Promising Data at ESMO GI 2025 for MSS Metastatic Colorectal Cancer Agenus Inc. has presented promising Phase 1 trial data on botensilimab and balstilimab for MSS metastatic colorectal cancer at ESMO GI 2025. The findings highlight improved response durability and overall survival, showcasing the potential of these therapies in cancer treatment.
May 12, 2025 Agenus Inc. Q1 2025 Financial Report: A Look at the Challenges and Opportunities Ahead Agenus Inc. reported a net loss of $25.32 million in Q1 2025, showing improvement from the previous year. Despite a revenue decline, strategic partnerships and reduced expenses signal potential for future growth amid ongoing financial challenges.
May 12, 2025 Agenus Inc Reports Q1 2025 Financial Results and Strategic Updates Agenus Inc. has reported encouraging Q1 2025 results, highlighting advancements in its botensilimab and balstilimab therapies. The company has also improved its financial efficiency and welcomed new leadership to strengthen its position in immuno-oncology.
May 12, 2025 Dr. Richard Goldberg Joins Agenus as Chief Development Officer Agenus has appointed Dr. Richard Goldberg as Chief Development Officer to advance its BOT/BAL program for GI cancers. With over 40 years of experience, Dr. Goldberg aims to improve patient outcomes and spearhead the company's regulatory strategies.
April 29, 2025 Agenus Inc. Set to Release First Quarter 2025 Financial Results Agenus Inc. is set to release its first quarter 2025 financial results on May 12, 2025, followed by a conference call for investors. This update will provide insights into their cancer treatment programs and strategic direction.
April 28, 2025 Agenus Inc. Reveals Promising Neoadjuvant Data for BOT/BAL in Pan-Cancer Study Agenus Inc. has unveiled promising data from its NEOASIS study, highlighting the BOT/BAL combination's effectiveness as a neoadjuvant treatment across solid tumors. The study showed significant pathological response rates, particularly in dMMR/MSI-H patients, with no dose-limiting toxicities, suggesting a favorable safety profile.
April 25, 2025 Agenus Inc. Presents Promising Data on BOT/BAL Combination Therapy for Liver Cancer at AACR 2025 Agenus Inc. presented promising Phase 1 study results for botensilimab (BOT) and balstilimab (BAL) combination therapy for advanced liver cancer at AACR 2025. The therapy showed a 17% overall response rate and a 72% disease control rate, indicating potential for patients who have exhausted standard treatments.
April 23, 2025 Agenus Announces Key Presentations for Botensilimab and Balstilimab at ASCO 2025 Agenus Inc. will showcase pivotal findings on botensilimab and balstilimab at ASCO 2025, focusing on metastatic colorectal and pancreatic cancers. The presentations will highlight innovative therapies and ongoing research aimed at enhancing treatment strategies for these challenging cancer types.
March 25, 2025 Agenus Inc. Showcases Promising BOT/BAL Data Ahead of AACR 2025 Agenus Inc. is set to present promising data on its BOT/BAL immunotherapy program at the AACR 2025. Key presentations include insights from the NEOASIS trial on early-stage cancers and a Phase 1 study on hepatocellular carcinoma, signaling significant advances in cancer treatment.
March 17, 2025 Agenus Inc. Reports Challenging Year in 2024 Annual Report Agenus Inc. has reported substantial financial losses and declining revenues in its 2024 annual report, prompting concerns over its long-term viability. With ongoing legal challenges and a pressing need for funding, the company must navigate a critical juncture as it aims to advance its innovative therapies.
March 11, 2025 Agenus Inc. Reports Strategic Improvements and Financial Results for Q4 and Full-Year 2024 Agenus Inc. reported its Q4 and full-year 2024 results, showcasing strategic cost reductions and advancements in its BOT/BAL program. The company aims to lower its operational burn rate to $50 million annually by mid-2025 while achieving promising clinical outcomes in cancer treatments.
February 26, 2025 Agenus Inc. Advances Cancer Immunotherapy with Promising Data from Key Conferences Agenus Inc. is pioneering advancements in cancer immunotherapy, focusing on innovative therapies like botensilimab and balstilimab. Recent data presented at major conferences highlights their potential in treating historically resistant cancers, including colorectal and gastroesophageal cancers, promising a transformative impact on patient outcomes.
February 25, 2025 Agenus Inc. to Showcase Innovations in Colorectal Cancer Treatment at B. Riley Securities Conference Agenus Inc. will present its innovations in colorectal cancer treatment at the B. Riley Securities Conference on February 28, 2025. Led by CCO Robin Taylor, Ph.D., the panel will discuss strategies to improve patient responses in this critical area of oncology.
February 25, 2025 Agenus Inc. to Release Q4 and Full Year 2024 Financial Results Agenus Inc. will release its Q4 and full-year 2024 financial results on March 11, 2025, followed by a conference call to discuss performance and strategic initiatives. The company aims to enhance its position in the immunotherapy market with ongoing clinical trials and innovative treatments.
February 24, 2025 Agenus Inc. Unveils Promising Botensilimab/Balstilimab Data for Gastric Cancer at AACR IO Annual Meeting Agenus Inc. unveiled promising data on botensilimab and balstilimab combined with agenT-797 for treating refractory gastric cancer at the AACR IO Annual Meeting. The combination therapy demonstrated enhanced immune activation and T-cell responses, marking a potential breakthrough in cancer treatment.
February 23, 2025 Agenus Inc. Highlights BOT/BAL in Upcoming AACR IO Annual Meeting Agenus Inc. is set to present its innovative BOT/BAL therapeutic combination at the AACR IO Annual Meeting, with key insights into its efficacy for gastric and colorectal cancers. The presentations will feature interim data from important Phase 2 studies, emphasizing advancements in cancer immunotherapy.
February 15, 2025 SWOT Analysis of Agenus Inc in 2025 This SWOT analysis examines Agenus Inc in 2025, detailing its strengths like a robust patent portfolio and innovative pipeline, while addressing weaknesses such as financial reliance and legal issues. The article also explores growth opportunities and competitive threats in the biotech sector.
February 12, 2025 Agenus Inc. Announces Key Presentations at AACR IO Annual Meeting Agenus Inc. will present key findings on its BOT/BAL combination therapy for cancer at the AACR IO Annual Meeting, highlighting data from Phase 2 and Phase 1/2 studies. The innovative treatments aim to improve responses in challenging cancer types, showcasing the company's commitment to advancing immunotherapy.
November 12, 2024 Agenus Inc. Reports Q3 2024 Financial Results: Challenges and Opportunities Ahead Agenus Inc. reports mixed Q3 2024 financial results with decreased revenue and increased losses. Despite challenges, the company advances its cancer immunotherapy pipeline and maintains key collaborations.
August 08, 2024 Agenus Inc. Reports Mixed Financial Results for Q2 2024 Agenus Inc. reported a net income of $6 million for H1 2024 but a net loss of $53.13 million for Q2. The company is focusing on reducing costs and expanding its cancer therapies.
May 07, 2024 Agenus Inc. Reports Q1 2024 Financial Results: A Year of Transition and Innovation Agenus Inc. reported no revenue in Q1 2024, a significant decline from the previous year, but managed to reduce expenses and improve its net loss. The company is undertaking strategic initiatives, including launching a new subsidiary and achieving milestones in clinical trials, while navigating financial challenges.
